Live
- Flood risk in low-lying areas of Chennai as Chembarambakkam Lake’s water level rises
- Pushpa 2 Theatre Canteen Owner Bites Customer’s Ear in Gwalior
- RG Kar tragedy: Statement of forensic doctor who took pictures of victim’s body crucial for CBI
- Include Valmiki community in ST list, MP Ambica pleads
- Nara Lokesh Urges Rapid Investment Approvals to Boost Employment in MSME Sector
- Chandrababu Advocates Strict Measures for Social Welfare and Infrastructure Development in AP
- Show of brotherhood by Vijayan, Stalin at event to honour Dravidian icon
- District Collectors’ conference with CM begins
- Celebrations kick off in Saudi Arabia to welcome FIFA World Cup 2034
- Google Unveils Jules AI to Help Developers Fix Code Errors
Moderna seeks regulatory approval for its Covid vaccine in India; Cipla applies for import
Moderna seeks regulatory approval for its Covid vaccine in India; Cipla applies for import
Mumbai-based pharmaceutical firm Cipla, on behalf of the US pharma major, has requested for import and marketing authorisation of these jabs.
New Delhi: India's drug regulator may soon grant restricted emergency use authorisation for Moderna's COVID-19 vaccine, official sources said on Tuesday.
Moderna has also informed that the US Government has agreed to donate a certain number of doses of the Moderna COVID-19 vaccine through COVAX to the Government of India for use and has sought approval from the Central Drugs Standard Control Organisation (CDSCO) for these vaccines.
Mumbai-based pharmaceutical firm Cipla, on behalf of the US pharma major, has requested for import and marketing authorisation of these jabs.
According to the sources, an approval is likely to come anytime as the CDSCO is in favour of doing so.
Cipla filed an application on Monday seeking permission for import of Moderna COVID-19 vaccine referring to DCGI notices dated April 15 and June 1 stating that if the vaccine is approved by the USFDA for EUA, the vaccine can be granted marketing authorization without bridging trial and assessment of safety data of first 100 beneficiaries of vaccines shall be submitted before rolling out in immunization programme.
